Global Guidance For Infant Spasms Still Varies

What was studied

This study reviewed clinical guidelines for infantile epileptic spasms syndrome (IESS) from around the world. It was not a study of babies receiving treatment directly. Instead, the authors compared what different national, regional, and institutional guidelines recommend for diagnosing and treating IESS.

The review included 28 guidelines in total: 16 published guidelines and 12 unpublished institutional protocols shared by pediatric neurologists. Fifteen came from high-income countries and 11 from low- and middle-income countries. The authors compared recommendations about tests, treatment recommendations, dosing, how soon to check if treatment is working, and follow-up monitoring.

What they found

Nearly all guidelines recommended an EEG for diagnosis. Brain MRI and genetic testing were recommended less consistently. For IESS linked to tuberous sclerosis complex, all guidelines recommended vigabatrin as first-line treatment.

The treatment advice changed over time. Older guidelines more often favored ACTH, while newer guidelines increasingly recommended prednisolone and vigabatrin. Combination treatment began appearing after 2017. Guidelines from low- and middle-income countries consistently recommended prednisolone, while guidelines from high-income countries more often recommended ACTH, vigabatrin, or combination therapy. Treatment response was most often assessed at about 14 days.

Limits of the evidence

This was a review of guidelines, not a trial comparing which treatment works best. It shows what experts recommend, but it cannot show that one approach leads to better outcomes than another.

Some guidelines were unpublished institutional protocols, which may not represent whole countries or regions. Not all parts of care were described the same way across documents. Differences between regions may reflect access, cost, and available testing, but this study did not directly test those reasons.

For families and caregivers

For families, this review suggests that there is broad agreement that IESS needs fast diagnosis and treatment, but the exact tests and medicines recommended can differ depending on where care is given. The authors suggest this may relate to differences in access, cost, and diagnostic resources.

It may help families know that EEG is widely seen as important, and that treatment response is often checked again after about 2 weeks. The review also shows that care practices have changed over time, with newer guidelines more often recommending prednisolone, vigabatrin, or both in some settings. This does not mean one plan is always best for every child, but it may help explain why doctors in different places recommend different options.

What to watch next

Further research is needed to help develop more standardized treatment protocols and practical international guidance, and to explore new treatment options for infants with IESS.

Terms in this summary

infantile epileptic spasms syndrome (IESS)

A serious epilepsy syndrome in babies that needs quick diagnosis and treatment.

epileptic encephalopathy

A brain condition in which epilepsy is associated with effects on development and brain function.

EEG

A test that records the brain's electrical activity.

MRI

A scan that makes detailed pictures of the brain.

genetic testing

Tests that look for changes in genes that may help explain a medical condition.

vigabatrin

A seizure medicine often used for infantile spasms, especially when linked to tuberous sclerosis complex.

ACTH

A hormone treatment used for infantile spasms.

tuberous sclerosis complex

A genetic condition that can be associated with seizures and growths in different parts of the body.